Search - tctmd.com

Displaying 61 - 80 of 334

Sort: Relevancy | Date

Presentation TCT 2021

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Presenter: Pieter Smits

November 05, 2021

Presentation TCT 2021

Latest HBR Clinical Evidence

Presenter: Marco Valgimigli

November 04, 2021

Presentation ESC 2021

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Presenter: Hirotoshi Watanabe

August 31, 2021

Presentation Fellows 2021

Fellows Course Connect Cases NSTEMI CASES

Presenter: Anu Tunuguntla

May 09, 2021

Presentation TCT 2020

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Presenter: Robert Byrne

October 17, 2020

Presentation TCT 2020

Coronary Stenting in High Bleeding Risk Patients: Is There a Preferred DES for Short DAPT?

Presenter: Davide Capodanno

October 15, 2020

Presentation TCT 2020

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

Presenter: Roxana Mehran

October 15, 2020

Presentation TCT 2020

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

Presenter: Robert Yeh

October 14, 2020

Presentation TCT 2020

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

Presenter: Sanjeevan Pasupati

October 14, 2020

Presentation TCT 2020

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

Presenter: Hao-Yu Wang

October 14, 2020

Presentation ACC 2020

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

Presenter: Yangsoo Jang

March 30, 2020

Presentation ACC 2020

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Presenter: William Hiatt

March 29, 2020

Presentation JIM 2020

Onyx in hbr-a case based

Presenter: Manoj Kumar

February 14, 2020

Presentation JIM 2020

Optimized DES for High ischemic risk & HBR patients: when efficacy and safety converge into one need

Presenter: Marco Valgimigli

February 13, 2020

Presentation JIM 2020

Ticagrelor Monotherapy Is the Right Choice!

Presenter: Roxana Mehran

February 12, 2020

Presentation BIT 2020

Dual Antiplatelet therapy: How Long to Continue after PC

Presenter: Baren Chakraborty

February 02, 2020

Presentation Controversies and Advances 2019

Optimal DAPT Strategies: Lessons Learned, Global Leaders, TWILIGHT, and More

Presenter: Roxana Mehran

November 15, 2019

Presentation Cardiovascular Interventions 2019

DAPT: Hot Topics in 2019

Presenter: Dean J. Kereiakes

November 01, 2019

Presentation TCT Abstracts Posters 2019

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Presenter: Young-Hyo Lim

October 21, 2019

Presentation TCT 2019

Case 3: A Patient With AF and ACS

Presenter: C. Michael Gibson

September 28, 2019

Advertisement

MASTER-DAPT: A Randomized Trial of Abbreviated Antiplatelet Therapy - Outcomes in High Bleeding Risk Patients With High Thrombotic and Ischemic Risk

Latest HBR Clinical Evidence

One-month Dual Antiplatelet Therapy Followed by Clopidogrel Monotherapy in Acute Coronary Syndrome:

Fellows Course Connect Cases NSTEMI CASES

COBRA-REDUCE: A Randomized Trial of a Thromboresistant Polyzene F-Coated Stent With 14 Days DAPT in High-Bleeding Risk Patients

Coronary Stenting in High Bleeding Risk Patients: Is There a Preferred DES for Short DAPT?

The XIENCE Short DAPT Program: XIENCE 90/28 - Evaluating the Safety of 3-month and 1-month DAPT in HBR Patients

TCT 381: Predictors of Ischemic and Bleeding Outcomes in High Bleeding Risk Patients Implanted With the SYNERGY Stent – A Post-Hoc Analysis From the EVOLVE Short DAPT Study

TCT 066: Ischemic and Bleeding Outcomes in Patients With vs. Without Atrial Fibrillation: Analysis From the Onyx ONE Month DAPT Program

TCT 060: Contribution of ESC DAPT Guideline-Endorsed High Thrombotic Risk Features to Long-Term Clinical Outcomes Among Patients With and Without High Bleeding Risk After PCI

Ticagrelor With or Without Aspirin in Acute Coronary Syndrome After PCI: Randomized Evaluation Of Ticagrelor Monotherapy After 3- month Dual-antiplatelet Therapy In Acute Coronary Syndrome The TICO trial

VOYAGER PAD Efficacy and Safety of Rivaroxaban in Patients with Symptomatic PAD undergoing Revascularization with and without Clopidogrel

Onyx in hbr-a case based

Optimized DES for High ischemic risk & HBR patients: when efficacy and safety converge into one need

Ticagrelor Monotherapy Is the Right Choice!

Dual Antiplatelet therapy: How Long to Continue after PC

Optimal DAPT Strategies: Lessons Learned, Global Leaders, TWILIGHT, and More

DAPT: Hot Topics in 2019

Comparison of Real-World Bleeding and Ischemic Event Rate in P2Y12 Inhibitors After Percutaneous Coronary Intervention: Analysis of Korean National Insurance Claims Data

Case 3: A Patient With AF and ACS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content